Gallium ga-68 gozetotide - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for gallium ga-68 gozetotide and what is the scope of patent protection?
Gallium ga-68 gozetotide
is the generic ingredient in three branded drugs marketed by Telix, Novartis, Univ Ca Los Angeles, and Univ Of Ca San Fran, and is included in four NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.Gallium ga-68 gozetotide has seventy-six patent family members in twenty countries.
Four suppliers are listed for this compound.
Summary for gallium ga-68 gozetotide
| International Patents: | 76 |
| US Patents: | 2 |
| Tradenames: | 3 |
| Applicants: | 4 |
| NDAs: | 4 |
| Finished Product Suppliers / Packagers: | 4 |
| Clinical Trials: | 3 |
| What excipients (inactive ingredients) are in gallium ga-68 gozetotide? | gallium ga-68 gozetotide excipients list |
| DailyMed Link: | gallium ga-68 gozetotide at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for gallium ga-68 gozetotide
Generic Entry Dates for gallium ga-68 gozetotide*:
Constraining patent/regulatory exclusivity:
Dosage:
POWDER;INTRAVENOUS |
Generic Entry Dates for gallium ga-68 gozetotide*:
Constraining patent/regulatory exclusivity:
Dosage:
POWDER;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for gallium ga-68 gozetotide
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Mayo Clinic | Phase 3 |
| University of California, San Francisco | Phase 1/Phase 2 |
| Prostate Cancer Foundation | Phase 1/Phase 2 |
Pharmacology for gallium ga-68 gozetotide
| Drug Class | Radioactive Diagnostic Agent |
| Mechanism of Action | Positron Emitting Activity |
US Patents and Regulatory Information for gallium ga-68 gozetotide
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Telix | ILLUCCIX | gallium ga-68 gozetotide | POWDER;INTRAVENOUS | 214032-001 | Dec 17, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Novartis | LOCAMETZ | gallium ga-68 gozetotide | POWDER;INTRAVENOUS | 215841-001 | Mar 23, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Univ Ca Los Angeles | GALLIUM GA 68 GOZETOTIDE | gallium ga-68 gozetotide | SOLUTION;INTRAVENOUS | 212642-001 | Dec 1, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Univ Of Ca San Fran | GALLIUM GA 68 GOZETOTIDE | gallium ga-68 gozetotide | SOLUTION;INTRAVENOUS | 212643-001 | Dec 1, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Novartis | LOCAMETZ | gallium ga-68 gozetotide | POWDER;INTRAVENOUS | 215841-001 | Mar 23, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for gallium ga-68 gozetotide
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Hungary | E053971 | ⤷ Try a Trial | |
| New Zealand | 729291 | Kit for radiolabelling with 68ga comprising a metal inhibitor | ⤷ Try a Trial |
| China | 106794265 | 用于使用68GA放射性标记的含金属抑制剂的试剂盒 (Kit for radiolabelling with 68ga comprising a metal inhibitor) | ⤷ Try a Trial |
| Australia | 2022202346 | Kit for radiolabelling with 68GA comprising a metal inhibitor | ⤷ Try a Trial |
| Canada | 3167294 | MONO-, DI- OU POLYSACCHARIDE UTILISE COMME INHIBITEUR METALLIQUE DANS LAPREPARATION D'AGENTS CIBLES FONCTIONNALISES DU CHELATE 68GA (MONO-, DI- OR POLYSACCHARIDE USED AS METAL INHIBITOR IN THE PREPARATION OF 68GA-CHELATE-FUNCTIONALIZED TARGETING AGENT) | ⤷ Try a Trial |
| Denmark | 3185911 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
